<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069001</url>
  </required_header>
  <id_info>
    <org_study_id>958</org_study_id>
    <nct_id>NCT03069001</nct_id>
  </id_info>
  <brief_title>Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV</brief_title>
  <official_title>Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Egyptian Patients With HCV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study was conducted at Ain Shams University Hospital, Internal Medicine,
      Hepatology and Gastroenterology Department, and Tropical Medicine Department.

      To compare the efficacy of the combination of sofosbuvir and simeprevir for 12 weeks with the
      combination of sofosbuvir and ribavirin for 24 weeks in Egyptian patients with HCV-related
      Child A cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation at end-of-treatment response</measure>
    <time_frame>12 weeks</time_frame>
    <description>undetectable HCV-RNA 12 weeks after the completion of therapy by a sensitive HCV-RNA assay</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>HCV</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir-Simeprevir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir 400 mg orally once-daily.
Simeprevir 150 mg orally once-daily.
Group A included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir-Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir 400 mg orally once-daily.
Ribavirin orally twice-daily (according to body weight: 1000 mg daily in patients with a body weight of &lt;75 kg and 1200 mg daily in patients with a body weight of â‰¥75 kg).
Group B included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir-Simeprevir</intervention_name>
    <description>-Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.</description>
    <arm_group_label>Sofosbuvir-Simeprevir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir-Ribavirin</intervention_name>
    <description>-Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.</description>
    <arm_group_label>Sofosbuvir-Ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic HCV infection with a positive HCV RNA level by PCR.

        Exclusion Criteria:

          -  Total bilirubin &gt; 2 mg/dl.

          -  serum albumin &lt; 2.8 g/dl.

          -  INR &gt; 1.7.

          -  platelet count &lt; 50000/mm3.

          -  serum creatinine &gt; 2.5 mg/dl.

          -  patients presented by ascites or hepatic encephalopathy.

          -  patients with evidence of other causes of liver diseases, including hepatitis A,
             hepatitis B, autoimmune hepatitis, alcoholic liver disease, drug-induced hepatitis,
             haemochromatosis, Wilson disease or alpha-1 antitrypsin deficiency.

          -  patients with any advanced systemic disease.

          -  pregnancy or inability to use effective contraception in females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Sara Abdelhakam</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>HCV treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

